A case of carcinoma of the lower alveolus and gingiva in which ^<18>FDG-PET was useful for assessing the therapeutic effects of concurrent intraarterial chemoradiotherapy
アイテムタイプ
紀要論文(ELS) / Departmental Bulletin Paper
言語
英語
キーワード
^<18>FDG-PET, 動注放射線同時併用療法, 口腔癌, 下顎歯肉癌
キーワード(英)
^<18>FDG-PET, concurrent intraarterial chemoradiotherapy, oral cancer, carcinoma of the lower alveolus and gingiva
Second Department of Oral and Maxillofacial Surgery, School of Dentistry, Iwate Medical University
Second Department of Oral and Maxillofacial Surgery, School of Dentistry, Iwate Medical University
Second Department of Oral and Maxillofacial Surgery, School of Dentistry, Iwate Medical University
Second Department of Oral and Maxillofacial Surgery, School of Dentistry, Iwate Medical University
Second Department of Oral and Maxillofacial Surgery, School of Dentistry, Iwate Medical University
Department of Dentistry and Oral Surgery, Mutsu General Hospital
For some time, we have performed concurrent intraarterial chemoradiotherapy for functional and morphological conservation in the treatment of oral cancer and have reported its usefulness. However, one of the disadvantages associated with concurrent therapy is difficulty in assessing post-therapeutic effects. Hence, since 1993, we have used positron emission tomography with 2 - deoxy- 2 - fluoro [^<18>F]-D-glucose (^<18>FDG-PET) for the assessment of therapeutic effects. Here, we report a patient with carcinoma of the lower alveolus and gingiva in whom ^<18>FDG-PET was performed to assess the effects of the present concurrent therapy and post-therapeutic recurrence and metastasis. In this patient, functional and morphological conservation was achieved, and post-therapeutic QOL was favorable. The patient was a 50-year-old woman who was diagnosed with squamous cell carcinoma of the lower alveolus and gingiva and was brought to our department to undergo therapy. At the initial visit, ^<18>FDG-PET showed 50-minute and 60-minute SUV (standardized uptake value) of 12.35±0.10 and 13.89±0.49, respectively, thus confirming an increase in SUV. After admission, the superficial temporal artery was cannulated, and 3 -drug chemotherapy [bleomycin (total dose: 60 mg), methotrexate (total dose: 200 mg) and cisplatin (total dose: 100 mg)] and radiotherapy (Linac, total dose: 40.25 Gy) were performed. After the concurrent therapy, the tumor shrunk and disappeared clinically, and ^<18>FDG-PET did not show a clear increase (50-minute value: 3.30±0.15; 60-minute value: 3.58±0.14). Hence, because a complete response (CR) was achieved, surgery could be avoided, and maintenance therapy was performed. At 2 years and 6 months after the end of the concurrent therapy, ^<18>FDG-PET showed low SUV (50-minute value: 1.91±0.16; 60-minute value: 1.90±0.02). So far, there has been no sign of recurrence or metastasis, and the clinical course has been favorable.
動注,放射線同時併用療法後の^<18>FDG-PETによる治療効果判定が有用であった下顎歯肉癌の1例
KJ00004579611
(2.79MB)
トップページ
岩手医科大学リポジトリ運用指針